Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study

Απλή σελίδα τεκμηρίου
dc.contributor.authorSkarlos, D. V.en
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorDimopoulos, M. A.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorRazis, E.en
dc.contributor.authorEconomopoulos, T.en
dc.contributor.authorPectasides, D.en
dc.contributor.authorGogas, H.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorKlouvas, G.en
dc.contributor.authorKyratzis, G.en
dc.contributor.authorAravantinos, G.en
dc.date.accessioned2015-11-24T19:15:06Z
dc.date.available2015-11-24T19:15:06Z
dc.identifier.issn0250-7005-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21452
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic useen
dc.subjectDeoxycytidine/administration & dosage/adverse effects/analogs & derivativesen
dc.subjectDoxorubicin/administration & dosage/adverse effectsen
dc.subjectDrug Administration Scheduleen
dc.subjectDrug Resistance, Multipleen
dc.subjectDrug Resistance, Neoplasmen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMiddle Ageden
dc.subjectOrganoplatinum Compounds/therapeutic useen
dc.subjectOvarian Neoplasms/*drug therapyen
dc.subjectTaxoids/therapeutic useen
dc.titleGemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II studyen
heal.abstractBACKGROUND: A phase II study was conducted to evaluate the efficacy and toxicity of the combination of gemcitabine (GEM) and pegylated liposomal doxorubicin (PLD) in patients with platinum- and/or taxane-resistant/refractory advanced epithelial ovarian cancer (AEOC). PATIENTS AND METHODS: Patients (pts), who had been treated with platinum or paclitaxel and met the criteria of resistant/refractory AEOC, received GEM 650 mg/m2 days 1 and 8 and PLD 25 mg/m2 day 1 every 4 weeks up to a total of 6 cycles, unless disease progression or adverse effects prohibited further therapy. RESULTS: Thirty-seven patients entered the study. There was 1 complete (3%) and 7 partial responses (19%) for an overall response rate of 22%. Two patients had stable disease (5.5%). After a median follow-up of 16.2 months, the median survival was 8.4 months and time to treatment failure 2.7 months. The most frequent severe toxicity was myelosuppression recorded in 13 (35%) patients. Severe stomatitis was recorded in only 2 (5%) cases and severe palmar-plantar erythrodysesthesia in 1 patient. One severe allergic reaction (grade 4) to PLD was recorded following the third cycle of treatment. CONCLUSION: The combination of GEM and PLD in patients with AEOC, who are resistant/ refractory to platinum and/or Taxanes, did not show any superiority over monotherapy. However, in view of the acceptable toxicity profile, the above combination may deserve further investigation in a randomised setting.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/16080573-
heal.journalNameAnticancer Resen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2005-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ